1464. Knowledge of Tuberculosis and Vaccine Trial Preparedness in Lima, Perú
Session: Poster Abstract Session: Global Health
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • Eileen Shu. IDSA Poster. Final.pdf (984.1 kB)
  • Background: A safe and effective vaccine would be an important strategy to improve tuberculosis control.  While its search is in early stages of development and testing continues, efficacy trials will require the participation of populations at highest risk, requiring community engagement and education campaigns.

    Methods: We assessed knowledge of TB, attitudes towards vaccines and willingness to participate in future efficacy TB vaccine trials, among 163 household contacts of recently diagnosed TB index cases in Lima, Peru, where the TB incidence rate is >130 cases/100,000.

    Results: 65.0% of participants were women, mean age was 38.7 years, and 4.9% had previously participated in clinical research. Overall knowledge of tuberculosis, vaccines and vaccine trial concepts was low (62.3%, 48.9% questions answered correctly, respectively). Only 38.7% of participants regarded their likelihood of acquiring TB in near future as high to extremely high, with 27.0% and 34.4% regarding their risk as average and low to extremely low, respectively. Almost half (49.1%) would probably (32.5%) or definitely (16.6%) participate in a clinical efficacy trial for a new TB vaccine. Of the remaining (50.9%), almost half (23.3%) were unsure while 16.6% and 11.0% were probably and definitely unwilling to participate.

    In multivariate analysis, willingness to participate was associated with desire to know more about TB risk factors and details of clinical trial (AOR 2.7, p=0.001) and age (AOR 1.02, p=0.039). Major motivators for participation were altruism, economic compensation, and potential protection from TB. Major barriers to participation were concern about side effects, social stigma, and potential change in future tuberculin sensitivity test (PPD) readings. 

    Conclusion: In Lima, Perú, barriers to participation in efficacy trials of TB vaccines exist even among high risk individuals. However, a desire for more knowledge of personal risk of TB and what a clinical efficacy trial would entail were highly associated with willingness to participate. Given the low perception of personal risk of TB, targeted education about TB risk factor and transmission is critical to increase the proportion willing to participate and lay the ground work for future vaccine trials.

    Eileen Shu1, Magdalena Sobieszczyk, MD, MPH2, Patricia Segura, RN, MPH3, Victor G Sal y Rosas, PhD4, Leonid Lecca, MD5, Jerome Galea, MSW5, Carmen C Contreras5, Jorge Sanchez, MD, MPH3 and Javier R Lama, MD, MPH3, (1)Columbia University, College of Physicians and Surgeons, New York, NY, (2)Medicine; Division of Infectious Disease, Columbia University, College of Physicians and Surgeons, New York, NY, (3)Asociación Civil Impacta Salud y Educación, Lima, Peru, (4)Pontificia Universidad Católica del Perú, Lima, Peru, (5)Partners in Health Perú, Lima, Peru


    E. Shu, None

    M. Sobieszczyk, None

    P. Segura, None

    V. G. Sal y Rosas, None

    L. Lecca, None

    J. Galea, Partners in health: Employee, Salary

    C. C. Contreras, None

    J. Sanchez, None

    J. R. Lama, None

    See more of: Global Health
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.